Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HL-1186 in moderate to severe acute postoperative pain
NCT07147049Phase 2Recruiting
- Sponsor
- Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.
- Start
- Aug 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute postoperative pain comparing HL-1186 with Placebo (2 arms). Primary endpoint: Sum of Pain Intensity Difference over 48 hours. Started Aug 2025; status: recruiting.
02
Drugs
HL-1186
03
Conditions
acute postoperative pain
Beyond the preview
Go deeper on NCT07147049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07147049.